Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Implantica publishes Interim Report January - September 2024 (Q3)
Significant events after the end of the period Significant events after the end of the period Financial summary third quarter 2024 First nine months Telephone conference Implantica will hold a teleconference on15 November 2024at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: WebcastIf you wish to participate via webcast, please use...
PR Newswire
15/11/2024
Noster Inc research: Celebrating Breakthroughs in Gut Microbiome
On October 10, the Symposium at NOSTER's Kyoto headquarters featured this year's winners, who shared insights on their pioneering discoveries related to the gut microbiome and its impact on health. Topics covered included the intricate interactions between gut bacteria, host organisms, and immune cells, as well as the potential of microbiome-based therapies. OnOctober 10, the Symposium at NOSTER'sKyotoheadquarters featured this year's winners, who shared insights on their pioneering...
PR Newswire
15/11/2024
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
COPENHAGEN, Denmark, November 15, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024. Revenue for the first nine months was DKK 3,622 million, and the operating profit (EBITDA) was DKK 692 million.Revenue from Travel Health increased by 18% to DKK 1,892 million compared to the first nine months of 2023 and revenue from Public Preparedness was DKK 1,549 million, which is...
Nasdaq GlobeNewswire
15/11/2024
Sandoz receives European Commission approval for Afqlir® (aflibercept), further…
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadershipBasel, November 15, 2024 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European...
Nasdaq GlobeNewswire
15/11/2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of…
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024...
Nasdaq GlobeNewswire
15/11/2024
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and…
As per DelveInsight's assessment, the total prevalent cases of presbyopia in the 7MM were ~325 million in 2023. These cases are expected to increase at a significant CAGR of 1.1% during the forecast period i.e., 2024–2034. Based on severity, presbyopia was bifurcated into mild and moderate to severe presbyopia, in EU4 and the UK, moderate to severe presbyopia accounted for the maximum number of cases, which was approximately 95 million. As per DelveInsight's assessment, the total prevalent...
PR Newswire
14/11/2024
miraDry Wins 2024 SHAPE Beauty Award for Excellence in In-Office Aesthetic…
miraDry's inclusion in this elite list highlights its unique contribution to the world of non-invasive aesthetic treatments. By addressing common concerns like excessive sweating and body odor in a way that is both effective and long-lasting, miraDry provides an accessible solution for people seeking to feel more confident and comfortable in their skin. miraDry's inclusion in this elite list highlights its unique contribution to the world of non-invasive aesthetic treatments. By addressing...
PR Newswire
14/11/2024
Akari Therapeutics Announces Successful Completion of Merger of Akari…
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov.14, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. (Peak Bio), creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. The combined entity will continue the two...
Nasdaq GlobeNewswire
14/11/2024
CHMP issues positive recommendation for approval of lecanemab in the EU
The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the Apolipoprotein E ε4 (ApoE ε4) gene. The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) or are non-carriers of the...
PR Newswire
14/11/2024
Spineway : a week dedicated to medical excellence with more than 20 surgeons…
Press release Ecully, November 14, 2024 – 6 p.m.Spineway: a week dedicated to medical excellence with more than 20 surgeons trained The Spineway Group, a, specialist in innovative implants for the treatment of severe spine disorders, organized a week of training dedicated to medical education from November 4 to 8, 2024. Through practical sessions in the operating room and on anatomical specimens in the laboratory, this intensive program trained over 20 international...
Nasdaq GlobeNewswire
14/11/2024
Press Release: Sequana Medical Announces New Share Capital Amount and New Number…
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARESGhent, Belgium, 14 November 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of a contribution in kind of receivables outstanding under the loan agreement entered into on 27 July 2020 between the Company and Belfius Insurance NV (as…
Nasdaq GlobeNewswire
14/11/2024
Groupe Casino - Nombre de droits de vote et d'actions 31-10-2024
CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2024(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
14/11/2024
Press Release: Sarclisa recommended for EU approval by the CHMP to treat…
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd aloneIf approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024...
Nasdaq GlobeNewswire
14/11/2024
Eisai Receives Positive Opinion from the CHMP in the European Union for…
TOKYO and CAMBRIDGE, Mass., Nov.14, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment...
Nasdaq GlobeNewswire
14/11/2024
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX
Per Fischer, Chief Executive Officer of MinervaX, said: "Veronica has been a key member of our board since October 2022 and her extensive vaccine development experience has been invaluable in the progress of our novel, prophylactic vaccine candidate against GBS. Veronica in her new role as Chair will oversee the next important phase of company development as we prepare for Phase III studies with our maternal GBS vaccine. I would like to thank Gerd for his valuable contributions to the…
PR Newswire
14/11/2024
Pneumonia Vaccine Market Poised for Significant Expansion: Projected to Achieve…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=209931 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=209931 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Pneumonia Vaccine Market Overview Geographic Dominance : The Pneumonia Vaccine Market exhibits distinct geographic dominance, with varying growth patterns across different regions.North AmericaandEuropeare currently...
PR Newswire
14/11/2024
Healthcare IT Market to Hit USD 834.35 Billion by 2029 with 14.7% CAGR |…
Browse in-depth TOC on "Healthcare IT Market" Browse in-depth TOC on "Healthcare IT Market" 320 - Tables 50 - Figures 420 - Pages Based on Components,the Healthcare IT market is segmented into services, software, and hardware. The largest share of the healthcare IT market was held by the services segment in 2023. The growth can be attributed to the following factors: healthcare organizations rely heavily on service providers for consulting, storage, implementation,...
PR Newswire
14/11/2024
PEGylated Proteins Market Set to Reach USD 19.1 Billion by 2031, Driven by…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=222584 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=222584 202 - Pages 126 – Tables 37 – Figures Scope Of The Report PEGylated Proteins Market Overview Geographic Dominance : North Americaholds a dominant position in the PEGylated Proteins Market, driven by a well-established pharmaceutical and biotechnology sector, advanced healthcare...
PR Newswire
14/11/2024
Protein Expression Market to Hit USD 4.82 Billion by 2029 with 7.1% CAGR |…
Browse in-depth TOC on "Protein Expression Market" Browse in-depth TOC on "Protein Expression Market" 632 - Tables 71 - Figures 470 - Pages Based on system type,the protein expression market is segmented into mammalian cell expression systems, prokaryotic expression systems, cell-free expression systems, yeast expression systems, insect cell expression systems, and algal-based expression systems. In 2023, the mammalian cell expression systems segment held the largest share...
PR Newswire
14/11/2024
Luxury Leaders Gather at the Neiman Marcus Awards to Honor Leonard A. Lauder
"Honoring Leonard Lauder tonight is especially meaningful. He transformed a brand created by his mother into a global icon and carries forward a legacy rooted in deep customer connection—a philosophy driving The Estée Lauder Companies' remarkable global business," said Geoffroy van Raemdonck, CEO, Neiman Marcus Group. "His vision has elevated luxury standards, reshaping industry possibilities and inspiring both innovation and elegance. We're excited to partner with ELC's brands to…
PR Newswire
14/11/2024
Lexogen launches Streamlined, Large-scale RNA-Seq Service for Blood Samples
At Lexogen NGS Services, the proprietary technologies are fully integrated into customizable, end-to-end Blood RNA-Seq Service workflows, available with RNA extraction from blood collection tubes and tailored data analysis. Blood-specific custom workflows, e.g., for efficient detection of isoforms and splice variants, are implemented. The newhigh-throughput RNA-Seq workflow for blood represents the most streamlined approach for blood transcriptomics screening and is now exclusively available as…
PR Newswire
14/11/2024
Coronado Research Limited announce the appointment of Alexander McCormick as…
Alexander commented, "I have collaborated with Andrew for many years within clinical research to drive innovation on multiple occasions. When Andrew laid out the mission and objectives of Coronado Research, I was excited by the opportunity to join such a strong leadership team. Our objective is to revolutionize the clinical research process and challenge the status quo of how we bring drugs to market today. I am very much looking forward to working with the team to bring positive change to…
PR Newswire
14/11/2024
Kerecis included on the list of covered products for Diabetic Foot Ulcers in the…
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) 1policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population.The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy 2earlier this year. The final...
Nasdaq GlobeNewswire
14/11/2024
IM Cannabis Reports Third Quarter Financial Results
Q3 2024 Financial Highlights Q3 2024 Financial Highlights Management Commentary "While the 66% growth we delivered inGermany, to reach$5.8Mthis quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025," said Oren Shuster, Chief Executive Officer of IMC. "Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation...
PR Newswire
14/11/2024
Altri Comunicati
